chlordiazepoxide has been researched along with Alcohol Drinking in 26 studies
Chlordiazepoxide: An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.
chlordiazepoxide : A benzodiazepine that is 3H-1,4-benzodiazepine 4-oxide substituted by a chloro group at position 7, a phenyl group at position 5 and a methylamino group at position 2.
Alcohol Drinking: Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.
Excerpt | Relevance | Reference |
---|---|---|
"Lorazepam was used as rescue medication." | 2.82 | A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome. ( Girish, K; Manjunatha, R; Nagraj, M; Pandit, LV; Pundarikaksha, HP; Shruthi, R; Vasundara, K; Vijendra, R; Vikram Reddy, K, 2016) |
"Buspirone was without important effects on the high alcohol preferring rats." | 1.29 | Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference. ( Meert, TF, 1993) |
"Three mothers of infants with holoprosencephaly consumed alcohol heavily in pregnancy." | 1.28 | Holoprosencephaly as a possible embryonic alcohol effect. ( Andrews, WL; Ronen, GM, 1991) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 17 (65.38) | 18.7374 |
1990's | 7 (26.92) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (7.69) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Manzo, L | 1 |
Donaire, R | 1 |
Sabariego, M | 1 |
Papini, MR | 1 |
Torres, C | 1 |
Girish, K | 1 |
Vikram Reddy, K | 1 |
Pandit, LV | 1 |
Pundarikaksha, HP | 1 |
Vijendra, R | 1 |
Vasundara, K | 1 |
Manjunatha, R | 1 |
Nagraj, M | 1 |
Shruthi, R | 1 |
WOLF, S | 1 |
FOXWELL, NH | 1 |
KURLAND, AA | 1 |
Roehrs, T | 1 |
Yang, O | 1 |
Samson, H | 1 |
Chan, AW | 2 |
Schanley, DL | 2 |
Leong, FW | 2 |
Brot, MD | 1 |
Koob, GF | 2 |
Britton, KT | 1 |
Criswell, HE | 1 |
Overstreet, DH | 1 |
Rezvani, AH | 1 |
Johnson, KB | 1 |
Simson, PE | 1 |
Knapp, DJ | 1 |
Moy, SS | 1 |
Breese, GR | 1 |
Rassnick, S | 1 |
D'Amico, E | 1 |
Riley, E | 1 |
Monti, PM | 1 |
Rohsenow, DJ | 1 |
Rubonis, AV | 1 |
Niaura, RS | 1 |
Sirota, AD | 1 |
Colby, SM | 1 |
Abrams, DB | 1 |
Meert, TF | 1 |
Söderpalm, AH | 1 |
Hansen, S | 1 |
Ritson, EB | 1 |
Palva, ES | 1 |
Linnoila, M | 1 |
Harris, RA | 1 |
Case, J | 1 |
Barrett, JE | 1 |
Weinberg, ES | 1 |
Underwood Ground, KE | 1 |
Ronen, GM | 1 |
Andrews, WL | 1 |
Gauvin, DV | 1 |
Harland, RD | 1 |
Criado, JR | 1 |
Michaelis, RC | 1 |
Holloway, FA | 1 |
Forney, RB | 1 |
Mello, NK | 1 |
Mendelson, JH | 1 |
Rosenberg, CM | 1 |
Waller, JA | 1 |
Belfer, ML | 1 |
Shader, RI | 1 |
Carroll, M | 1 |
Harmatz, JS | 1 |
Milner, G | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence[NCT01549652] | 133 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
Intervention | units on a scale (Mean) |
---|---|
Prevention of Opioid Withdrawal | -0.44 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
Intervention | units on a scale (Mean) |
---|---|
Prevention of Opioid Withdrawal | -2.68 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
Intervention | units on a scale (Mean) |
---|---|
Prevention of Opioid Withdrawal | -2.59 |
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
Intervention | units on a scale (Mean) | |
---|---|---|
Change in BDIS (Ondansetron) | Change in BDIS (Placebo) | |
Prevention of Physical Dependence | -0.6 | 0.2 |
"Originally developed by Handelsman, the Objective Opioid Withdrawal Scale (OOWS) score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The minimum score of 0 means the patient is not showing any signs of opioid withdrawal. The maximum score of 13 signifies all signs of opioid withdrawal to the largest extent possible.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If deemed necessary by the clinician, participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
Intervention | units on a scale (Mean) | |
---|---|---|
Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
Prevention of Opioid Withdrawal | 3.6 | 3.6 |
"Originally developed by Handelsman, the OOWS score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The maximum score is 13 and suggests the patient is showing all signs of opioid withdrawal to the largest extent possible. The minimum score of 0 suggests the patient is not showing any signs of opioid withdrawal.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
Intervention | units on a scale (Mean) | |
---|---|---|
Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
Prevention of Physical Dependence | 4.5 | 4.2 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
Intervention | units on a scale (Mean) | |
---|---|---|
Change in VAS Score (Ondansetron) | Change in VAS Score (Placebo) | |
Prevention of Physical Dependence | -2.9 | -2.8 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
Intervention | units on a scale (Mean) | |
---|---|---|
Change in RMDI (Ondansetron) | Change in RMDI (Placebo) | |
Prevention of Physical Dependence | -4.6 | -2.0 |
The Subjective Opioid Withdrawal Score (SOWS) score is calculated as the sum of 16 subjective patient-reported symptom scores rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
Intervention | units on a scale (Mean) | |
---|---|---|
Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
Prevention of Opioid Withdrawal | 12.5 | 12.2 |
The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
Intervention | units on a scale (Mean) | |
---|---|---|
Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
Prevention of Physical Dependence | 16.4 | 12.0 |
Profile of Mood States (POMS) is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
Intervention | units on a scale (Mean) | |
---|---|---|
Change in POMS Score (Ondansetron) | Change in POMS Score (Placebo) | |
Prevention of Opioid Withdrawal | 29.3 | 28.3 |
(Profile of Mood States) POMS is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
Intervention | units on a scale (Mean) | |
---|---|---|
Change in POMS (Ondansetron) | Change in POMS (Placebo) | |
Prevention of Physical Dependence | 36.1 | 29.2 |
1 review available for chlordiazepoxide and Alcohol Drinking
Article | Year |
---|---|
Anxiolytic effects of steroid hormones during the estrous cycle. Interactions with ethanol.
Topics: Alcohol Drinking; Anesthetics; Animals; Anxiety; Appetitive Behavior; Arousal; Brain; Chlordiazepoxi | 1995 |
4 trials available for chlordiazepoxide and Alcohol Drinking
Article | Year |
---|---|
A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome.
Topics: Adult; Alcohol Drinking; Baclofen; Chlordiazepoxide; Diazepam; Humans; Lorazepam; Male; Middle Aged; | 2016 |
Effect of active metabolites of chlordiazepoxide and diazepam, alone or in combination with alcohol, on psychomotor skills related to driving.
Topics: Adult; Alcohol Drinking; Automobile Driving; Chlordiazepoxide; Clinical Trials as Topic; Diazepam; D | 1978 |
International seminar research on alcohol, drugs and driving.
Topics: Alcohol Drinking; Auditory Perception; Automobile Driving; Caffeine; Chlordiazepoxide; Clinical Tria | 1973 |
Drug maintenance in the outpatient treatment of chronic alcoholism.
Topics: Adult; Alcohol Drinking; Alcoholic Intoxication; Alcoholism; Automobile Driving; Boston; Chlordiazep | 1974 |
21 other studies available for chlordiazepoxide and Alcohol Drinking
Article | Year |
---|---|
Anti-anxiety self-medication in rats: oral consumption of chlordiazepoxide and ethanol after reward devaluation.
Topics: Alcohol Drinking; Animals; Anti-Anxiety Agents; Anxiety; Chlordiazepoxide; Conditioning, Operant; Di | 2015 |
INCIDENCE OF DRINKING AMONG HOSPITALIZED CONVALESCING ALCOHOLICS.
Topics: Alcohol Drinking; Alcoholics; Alcoholism; Chlordiazepoxide; Convalescence; Hospitalization; Humans; | 1965 |
Chlordiazepoxide's interaction with ethanol intake in the rat: relation to ethanol exposure paradigms.
Topics: Alcohol Drinking; Animals; Body Weight; Chlordiazepoxide; Diet; Drug Interactions; Environment; Etha | 1984 |
Long-lasting reduction in ethanol selection after involuntary intake of ethanol/chlordiazepoxide.
Topics: Alcohol Drinking; Animals; Chlordiazepoxide; Drinking Behavior; Ethanol; Food Preferences; Male; Mic | 1983 |
Influence of chlordiazepoxide on alcohol consumption in mice.
Topics: Alcohol Drinking; Animals; Chlordiazepoxide; Male; Mice; Mice, Inbred C57BL; Taste; Time Factors | 1983 |
Effects of ethanol, MK-801, and chlordiazepoxide on locomotor activity in different rat lines: dissociation of locomotor stimulation from ethanol preference.
Topics: Alcohol Drinking; Animals; Arousal; Chlordiazepoxide; Dizocilpine Maleate; Dose-Response Relationshi | 1994 |
GABA antagonist and benzodiazepine partial inverse agonist reduce motivated responding for ethanol.
Topics: Alcohol Drinking; Animals; Appetitive Behavior; Arousal; Azides; Benzodiazepines; Brain; Chlordiazep | 1993 |
Alcohol cue reactivity: effects of detoxification and extended exposure.
Topics: Adaptation, Psychological; Adult; Alcohol Drinking; Alcohol Withdrawal Delirium; Alcoholism; Arousal | 1993 |
Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference.
Topics: Alcohol Drinking; Alcoholism; Animals; Buspirone; Chlordiazepoxide; Citalopram; Dose-Response Relati | 1993 |
Benzodiazepines enhance the consumption and palatability of alcohol in the rat.
Topics: Alcohol Drinking; Animals; Anti-Anxiety Agents; Brain; Chlordiazepoxide; Diazepam; Dose-Response Rel | 1998 |
Psychological medicine. Treatment of alcoholism.
Topics: Adolescent; Adult; Alcohol Drinking; Alcohol Withdrawal Delirium; Alcoholics Anonymous; Alcoholism; | 1975 |
Effects of maternal consumption of ethanol, barbital, or chlordiazepoxide on the behavior of the offspring.
Topics: Alcohol Drinking; Animals; Animals, Newborn; Avoidance Learning; Barbital; Barbiturates; Behavior, A | 1979 |
Effects of chlordiazepoxide on schedule-induced water and alcohol consumption in the squirrel monkey.
Topics: Alcohol Drinking; Animals; Chlordiazepoxide; Drinking Behavior; Haplorhini; Male; Reinforcement Sche | 1975 |
Impaired pilot performance: drugs or alcohol.
Topics: Accidents, Aviation; Aerospace Medicine; Alcohol Drinking; Chlordiazepoxide; Ethanol; Humans | 1975 |
Holoprosencephaly as a possible embryonic alcohol effect.
Topics: Abnormalities, Drug-Induced; Alcohol Drinking; Chlordiazepoxide; Female; Holoprosencephaly; Humans; | 1991 |
The discriminative stimulus properties of ethanol and acute ethanol withdrawal states in rats.
Topics: Affect; Alcohol Drinking; Alcohol Withdrawal Delirium; Alcoholic Intoxication; Animals; Arousal; Chl | 1989 |
Behavioral studies of sleep patterns in alcoholics during intoxication and withdrawal.
Topics: Adult; Alcohol Drinking; Alcoholism; Chlordiazepoxide; Ethanol; Hallucinations; Humans; Hypnotics an | 1970 |
Clinical depression of the central nervous system due to diazepam and chlordiazepoxide in relation to cigarette smoking and age.
Topics: Adult; Age Factors; Aged; Alcohol Drinking; Anxiety; Brain; Chlordiazepoxide; Depression, Chemical; | 1973 |
Drugs and highway crashes. Can we separate fact from fancy?
Topics: Accidents, Traffic; Age Factors; Alcohol Drinking; Automobile Driving; Cannabis; Chlordiazepoxide; C | 1971 |
Alcoholism in women.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Anxiety; Chlordiazepoxide; Depression; Diazepam; Female; | 1971 |
Drinking and driving in 753 general practice and psychiatric patients on psychotropic drugs.
Topics: Alcohol Drinking; Amitriptyline; Automobile Driving; Barbiturates; Chlordiazepoxide; Diazepam; Drug | 1969 |